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Abstract: Atherosclerotic cardiovascular disease is the leading cause of death and a major 
part of its pathophysiology remains obscure. Some hematological targets have been related to 
the development and clinical outcome of this disease, especially soluble cytokines, leukocytes, 
red blood cells, hemostatic factors and platelets, and bone-marrow vascular progenitors. 
These emerging factors may be modulated by current antiatherosclerotic pharmacotherapy, 
target-designed novel drugs or progenitor cell therapy. The aim of current review article is to 
comprehensively review the role of these antiatherosclerotic targets and therapy.
Keywords: atherosclerosis, blood, progenitor cells, cytokines, therapy
Emerging hematological targets
for cardiovascular disease
Historical development
Cardiovascular disease is the leading cause of death and disability (Ezzati et al 2005). In 
the last years of the 20th century the role of inﬂ  ammation in atherosclerosis was widely 
recognized (Ross et al 1999), according to previous hypotheses (Virchow 1858).
Nevertheless, a mere tissue and innate immunity-mediated response to local 
inﬂ  ammation did not ﬁ  t several observations. First was the coincidence of different 
atherosclerotic locations (coronary, aortic, carotid), at a simultaneous degree of evo-
lutionary state (Helft et al 2002). Second was the the growing concern of accelerated 
atherosclerosis in autoimmune diseases (Shoenfeld et al 2005), which highlighted the 
importance of acquired immunity in this vascular disorder (Hansson and Libby 2006). 
The third event was the discovery of bone-marrow derived progenitor cells that were 
able to differentiate towards the endothelial lineage in animal models (Asahara et al 
1997) and humans (Vasa et al 2001a), being the medical importance of these progeni-
tors an emerging matter of interest (Hristov et al 2003).
Soluble inﬂ  ammatory mediators 
in atherosclerosis
The approach of atherosclerosis as an inﬂ  ammatory disease led to the search of 
inﬂ  ammatory markers (reviewed in Table 1). Several of these molecules include: 
interleukin (IL)-1 (Ikonomidis et al 1999), IL-ra (Rothenbacher et al 2005), tumor 
necrosis factor (TNF) (Naya et al 2007), IL-6 (Langenberg et al 2006), and monocyte 
chemotactic protein-1 (MCP-1) (Hoogeven et al 2005). However, although these mark-
ers seem to be elevated in atherosclerotic patients compared to disease-free controls, 
their lack of speciﬁ  city seems to be the most important limitation.
In atherosclerosis, a misbalance between T-helper-1/T-helper-2 (Th1/Th2) function 
seems to take place (Szodoray 2006). Th1 function (mediated by the cytokines interferon 
(IF)-γ, TNF-α) is regarded as proatherogenic, whereas Th2 (mediated by IL-4, IL-5) Biologics: Targets & Therapy 2008:2(3) 398
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is considered as protective (Hansson and Robertson 2004). 
Balance is mediated by Th3 function, which may regulate 
transition from Th1 to Th2 by the cytokines IL-10 and tumor 
growth factor (TGF)-β1 (Redondo et al 2007a). However, 
although serum levels of active and total fraction of TGF-
β1 have been related to both the protection against an acute 
coronary event (Grainger et al 1995) and the development 
of chronic atherosclerosis lesions (Laviades et al 2000), the 
implementation of blood levels of TGF-β1 for atherosclerosis 
diagnosis has remained elusive (Redondo et al 2007a).
Among all biochemical blood inﬂ  ammatory markers for ath-
erosclerosis, C-reactive protein (CRP) has been studied deeply 
(Ridker 2003). This protein is secreted by the liver in response 
to serum IL-6 and activated from pentameric to monomeric on 
the vessel wall, where it enhances inﬂ  ammatory cell recruitment, 
platelet adhesion and thrombosis (Khreiss et al 2004). Large 
clinical evidence linked blood levels of high-sensitivity measured 
CRP as an independent marker for subclinical atherosclerosis 
(Thakore et al 2007), cardiovascular disease severity (Bansal and 
Ridker 2007), and the coming of future cardiovascular events 
(Blake et al 2003; Bansal and Ridker 2007). However, more 
recent clinical evidence subsequently showed the limitations of 
this marker as an independent risk factor (Fortmann et al 2004; 
Wilson et al 2005; Lloyd-Jones et al 2006).
Leukocytes
White cell count has been established as an independent 
marker of subclinical atherosclerosis (Sen et al 2007). 
Moreover, this widely available parameter may be a sensitive 
predictor of the coming of future coronary events (Haim et al 
2004) and long-term mortality (Núñez et al 2005).
The role of leukocytes in atherosclerosis was first 
recognized for the monocyte/macrophage lineage. Pathologic 
specimens have always shown the accumulation of macro-
phages in the extreme zone of atherosclerotic lesions (the 
plaque shoulder), which make them more prone to rupture 
and thrombosis (Fuster et al 2005). These inﬂ  ammatory 
macrophages are positive for CD36+, a scavenger receptor 
which facilitates the uptake of small and dense oxidized 
low-density lipoprotein (LDL) particles and gives them 
the appearance of foam cells (Martin-Fuentes et al 2007). 
These foam cells become inﬂ  ammatory enhancers, which 
precipitate the plaque instability (Kuchibhotla et al 2008). 
Circulating monocytes, the blood precursors of macrophages, 
have also been implicated in atherosclerosis. Clinical whole 
monocyte count precedes the coming of coronary (Madjid 
et al 2004) and cerebrovascular (Johnsen et al 2005) events, 
as well as subclinical carotid stenosis (Chapman et al 2004). 
Moreover, a direct correlation has been found for monocyte 
count and infarct size (Meisel et al 1998). Monocyte con-
centration has equally been inversely correlated to eventual 
ejection fraction after ischemia (Maekawa et al 2002). 
After coronary artery bypass grafting these monocytes lose 
the membrane receptor CD14+ and secrete soluble CD14+ 
to plasma, a general mechanism in monocyte activation 
(Fingerle-Rowson 1998).
Another leukocyte type with emerging importance in 
atherosclerosis is the lymphocyte, since a signiﬁ  cant accu-
mulation of lymphocytes has been reported in histological 
studies (Fuster et al 2005). They are mostly T cells (CD3+), 
with helper function (CD4+) which participate in plaque 
instability by secretion of cytokines, specially associated 
with the Th1 phenotype (Hansson and Robertson 2006). In 
order to regulate this atherogenic immune response, several 
experimental attempts in animal models have been made 
with vaccines to induce antibodies secretion and further 
elimination of oxidized LDL (Binder et al 2003), or immu-
nological tolerance for HSP65 (Harats et al 2002).
An increasing amount of experimental and clinical 
evidence highlights the importance of neutrophils in 
atherosclerosis. Neutrophils have been shown to predict 
clinical coronary stenosis (Avanzas et al 2004). These clinical 
observations have been reproduced in experimental condi-
tions. In the apoE-/- mice model, disruption of the SDF/
CXCR4 by the drug AMD3100 increased bone marrow 
production, blood levels and atherosclerotic inﬁ  ltration of 
Table 1 Inﬂ  ammatory factors at the vessel wall level
Molecule Role
IL-1 Initiator of cell adhesion molecule expression
IL-ra IL-1 receptor antagonist (soluble endogenous inhibitor)
MCP-1 Monocytic chemo-attracting protein
TNF-α Induces cell apoptosis, inﬂ  ammation, and adhesion
IL-6 Soluble trigger for hepatic CRP release
IF-γ Interferon gamma, macrophage stimulus
IL-4 and 5 Typical Th2 cytokines
IL-10 Th2 inducer
TGF-β1 Modulates inﬂ  ammation, cell growth and differentiation
CRP C-reactive protein, induces endothelium activation
CD36 Stimulus for cholesterol uptake and foam cell transformation
HSP65 Heat shock protein, initiator of intracellular inﬂ  ammation
SDF Induces stem and inﬂ  ammatory cell adhesion/migration
CXCR4 Chemokine family receptor for SDF
PDGF Potent mitogenic factor for vascular smooth muscle
Abbreviations: CRP,   C-reactive protein;   IF,   interferon;   IL,   interleukin;   TGF,   tumor 
growth factor;   TNF,  tumor necrosis factor;  PDGF,  platelet-derived growth factor; SDF, 
stromal-derived factor.Biologics: Targets & Therapy 2008:2(3) 399
Hematology and therapy for cardiovascular disease
neutrophils, an event which was able to be prevented by 
anti-neutrophil antibody injection (Zernecke et al 2008).
Red blood cells
Red blood cells (RBC) precipitate intraplaque hemorrhage, 
which leads to plaque instability. Large extracellular cho-
lesterol crystals in unstable atherosclerotic plaques come 
from the membrane cholesterol of senescent RBC after 
intraplaque hemorrhage (Kolodgie et al 2003). Circulating 
RBC are able to dampen vessel oxidative damage by means 
of their antioxidant machinery (glutathione), a physiologi-
cal role closely related to their ability to uptake, carry and 
release nitric oxide (NO), thus enhancing local vasodilation 
and prevention of ischemia (Minetti et al 2007). However, 
when local inﬂ  ammatory and oxidative stimulus is strong 
enough to surpass their capability, RBC behave as “oxidative 
bullets”, extending the oxidative damage by ONOO- trans-
port (Denicola et al 1998). Ischemic and oxidative damage 
to RBC increases membrane phosphatidylserine (Setty and 
Betal  2008), become aggregated among them (an event 
mediated by ﬁ  brinogen) and to the surrounding endothelium 
(mediated by thrombospondin) (Minetti et al 2007). RBC 
damage and loss of their physiological antioxidant and 
anti-ischemic role is a frequent complication of unstable 
hemoglobin conditions, such as sickle cell disease and 
thallassemia, where there is a vicious circle between RBC 
dysfunction and ischemia (Raman et al 2006).
Extracorpuscular hemoglobin is able to behave as a 
powerful proinﬂ  ammatory and oxidative factor. Extracor-
puscular hemoglobin can be inactivated by haptoglobin (Hp). 
Interestingly, Hp genotype may mediate the extent of this 
protective response. The Hb1 allele may exert a protective 
role in atherosclerosis whereas the Hb2 allele is associated 
to increased infarct size in diabetic patients and a poorer 
response to antioxidant therapy (Levy et al 2007).
Hemostatic factors
Hemostasis is closely related to macrophage-mediated 
inﬂ  ammation, since oxidized LDL is able to increase mac-
rophage apoptosis by the caspase-3 pathway, wich eventu-
ally triggers tissue factor activation and initiation of the 
extrinsic coagulation cascade (Hutter et al 2004). Thus, the 
capability of an atheromatous plaque to become clinically 
signiﬁ  cant seems to be closely correlated to its thrombotic 
capability rather than the mere mechanical disruption. 
Therefore, current nomenclature highlights the concept high-
risk plaque rather than fragile plaque (Fuster et al 2005), 
since thrombosis is a key issue not only from the high-risk 
atheromatous plaque but also from the blood of the whole 
high-risk patient (Corti et al 2003). Type 2 diabetes mellitus 
increases the inﬂ  ammatory and pro-coagulant state of the 
blood when it passes through a Badimon chamber (Osende 
et al 2001). Hypercholesterolemia, especially when associ-
ated with small, dense and oxidized LDL particles, is equally 
able to increase blood coagulability in vitro (Ananyeva 
et al 2002) and in vivo (Bai et al 2006). Statins are able to 
decrease the procoagulant trend in atherosclerotic patients 
(Kadikoylu et al 2003).
Tissue factor is up-regulated in atherosclerosis (Furnkranz 
2005), especially in areas of plaque rupture (Crawley et al 
2000). In cell culture experiments, a wide variety of in vitro 
atherosclerotic putative triggers (CRP, cholesterol esters, glu-
cose, angiotensin) are able to increase the acivity of tissue fac-
tor in cultured macrophages and vascular smooth muscle cells 
(Cirillo et al 2005), an event prevented by in vitro incubation 
with anti-atherosclerotic drugs, such as statins (Dietzen et al 
2007) and antiplatelet drugs (Camera  et al 2003). Blood 
ﬁ  brinogen is also closely related to atherosclerosis, since it is 
triggered by IL-6 (Lowe et al 2004) and correlated to artery 
occlusion (Nylaende et al 2006).
Platelets are involved in the atherosclerotic process. They 
form the ﬁ  rst hemostatic defense; therefore they initiate and 
trigger the atheromatous instability (Fuster et al 2005). This 
fact may explain the beneﬁ  ts of antiplatelet drugs in the 
secondary prevention of myocardial infarct and unstable 
angina (ATC 1994). Aspirin inhibits plaque aggregation 
by irreversible acetylation of Ser530 of COX-1 (Awtry and 
Loscalzo 2000). Clopidogrel inhibits platelet function by 
inhibition of ADP receptor. These two antiplatelets can be 
combined (ATC 2002). However, current evidence-based 
indications of combined therapy have not been established 
in the prevention of cardiovascular events (Bhatt et al 2006) 
and are restricted to the post-stent situation (Bertrand et al 
2000) and when a lone drug proves unable to achieve clinical 
success (Dropinski et al 2007). Related to this, the concept 
of “aspirin resistance” has emerged in recent years. It may be 
referred as this lack of clinical antiplatelet control (clinical 
aspirin resistance), persistence of high platelet activity (in 
vitro resistance) or persistence of elevated serum or plasma 
markers of platelet activity (resistance measured as sur-
rogate markers) (Michelson et al 2005). Aspirin resistance 
(measured as the urinary concentration of thromboxane) has 
been shown to be an independent cardiovascular risk factor 
(Eikelboom et al 2002).
Increased platelet activity may trigger endothelial dam-
age (Nomura et al 2001). This vascular pro-inﬂ  ammatory Biologics: Targets & Therapy 2008:2(3) 400
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role for the platelets is played by their secretory granules, 
which secrete chemokines for leukocyte adhesion (Weber 
2005), platelet-derived growth factor (PDGF) as a potent 
growth factor for vascular smooth muscle cells (Lamb et al 
2001) and TGF-β1. TGF-β1 is an antiinﬂ  ammatory cytokine 
which seems to lose this physiological role in atherosclerosis, 
where it becomes proﬁ  brotic and possibly induces vascular 
progenitor differentiation towards the smooth muscle lineage 
(Redondo et al 2007a).
Vascular progenitors
Although the existence of a unique progenitor for blood and 
vessel cells (the hemangioblast) has classically been accepted 
in embryos, the extension of this concept to adult animals 
took place in 1997 (Asahara et al 1997). Further studies in 
human beings determined the importance of these progenitors 
in vascular self-repair. Endothelial progenitor cells (EPCs) 
are originated in the bone marrow, from CD34+ stem cells 
(Hristov et al 2003). Enzyme disruption from the stromal 
cell-derived factor-1 (SDF-1)-rich matrix by matrix metallo-
peptidase 9 (MMP-9) releases c-kit ligand and allows the exit 
of these cells from the bone marrow, a process which requires 
a sufﬁ  cient blood, vascular and oxygen supply (Hristov and 
Weber 2004). Early EPCs are positive for several markers, 
such as CD34+, CD133+, and KDR+. Early EPCs circulate 
in blood, home to the denuded endothelium, differentiate to 
endothelial cells (a process where they acquire CD144+ and 
vVW+) and thus repopulate the endothelium or secrete local 
paracrine factor to increase the physiological state of resident 
cells (Ingram et al 2005; Bardoff and Dimmeler 2006). The 
homing of these cells is regulated by several chemokines 
such as CXCR4 (Hristov et al 2007a).
The ﬁ  rst in vitro characterizations of putative EPCs were 
done by uptake of acetylated low density lipoprotein and Ulex 
europaeus lectin binding and these capabilities were shown to 
be shared by monocytes. This evidence led to some research 
groups to re-consider the property of the term EPC instead of 
circulating angiogenic cells (Rehman et al 2003). It may be 
considered that the heterogeneous EPC progeny evolves from 
the CD34+ stem cell and acquire monocytic (CD14+) and/or 
endothelial markers (subsequently CD133+, KDR+, CD144+, 
and vVW+) (Rohde et al 2006). The role of these cells types is 
double: ﬁ  rst is to patch and re-populate the endothelial layer 
(Op den Buijs 2004; Ingram et al 2005). Second is to behave 
of tissue stimulators for resident endothelial cells (Nakul-
Aquaronne 2003; Rehman et al 2003; Rohde et al 2006).
Clinical studies show a close correlation between the 
in vitro EPC colony forming units (CFUs) and the in vivo 
endothelial function (Hill et al 2003). CFU capability, 
endothelial marker expression and proliferation are dampened 
when EPCs are incubated with proatherosclerotic trig-
gers (LDL-cholesterol, angiotensin) (Imanishi et al 2005; 
Pellegatta et al 2006).
Blood levels of EPCs are inversely correlated to 
Framingham risk factors (Vasa et al 2001b) and to the direct 
angiographic coronary obstruction (Kunz et al 2006). Low 
EPC count in patients precedes the coming of atherosclerotic 
events (Schmidt-Lucke et al 2005) and can be increased by 
statin treatments (Dimmeler et al 2001; Vasa et al 2001a). 
However, this putative protective role of EPCs is faced by the 
fact that their number increases after a heart infarct (Leone 
et al 2005), although EPC capability to form in vitro CFUs 
remains diminished in patients with coronary heart disease 
(Liguori et al 2007) and this post-infarct CFU impairment 
is associated to post ischemic heart failure (Kissel 2007). 
Animal models show an increased atherosclerotic growth 
when cultured EPCs are infused (George et al 2005). Clini-
cal studies also show a decreased EPC after long-term statin 
treatment (Hristov et al 2007b). Other study shows a direct 
correlation between angiographic coronary obstruction and 
EPC number (Güven et al 2006). In addition, a large and 
recent population-based study shows a direct correlation 
between Framingham’s risk factors and EPC number; a 
similar correlation is not found in CFU (Xiao et al 2007). 
This apparent lack of consensus may be explained by the lack 
of one uniﬁ  ed deﬁ  nition of EPC, based on stem ontogeny, 
transcription factors and markers (Leor and Marber 2006). 
Another factor to explain this heterogeneity is the depen-
dence on the evolutionary state. In chronic heart failure EPC 
concentration is increased as a putative defense mechanism 
against an ischemic insult, although it becomes decreased in 
more advanced disease states (Valgimigli et al 2004).
Bone marrow can also produce smooth muscle progenitor 
cells (SPCs), which may possess the capability to increase 
intima-media thickness and neointimal restenosis (Sata et al 
2002), although their role in primary atherosclerosis has been 
shown to be minimal (Bentzon et al 2007). Atherosclerotic 
patients have a higher blood concentration of CD14+/CD105+ 
cells, which give raise to SPC in culture (Sugiyama et al 
2006). CD105+ or endoglin is an accessory receptor of TGF-
β1 which may regulate differentiation towards the smooth 
muscle lineage (Redondo et al 2007a). CD14+ is monocyte 
marker which is shared by a wide variety of vascular progen-
itors (Rehman et al 2003). An unresolved mystery is whether 
EPCs and SPCs come from a unique progenitor or come 
from different circulating early progenitors which may use Biologics: Targets & Therapy 2008:2(3) 401
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different adherence systems (Hoofnagle et al 2004; Ingram 
et al 2005). Related to this, endothelial to mesenchymal 
transition has been described in mice embryo. Interestingly, 
in this model endothelial to mesenchymal progress was 
enhanced by TGF-β1 (Zeisberg et al 2007).
Emerging hematological therapies 
for cardiovascular disease
Progenitor cell therapy
Pioneer experimental therapeutic attempts on animal 
models were able to show that in vivo infusion of bone 
marrow-derived EPCs improved heart and hind limb isch-
emia. These results suggested that, although a deregulation 
of EPC function seem to take place in ischemia, artiﬁ  cial 
self-transplantation may overcome the lack of bone marrow 
release, blood destruction, lack of adhesion, or abnormal 
differentiation.
Initial evidence has demonstrated the feasibility and 
safety of intracoronary infusion of EPCs (Rosenzweig 2006). 
The majority of clinical evidence to date is obtained in tri-
als where bone marrow-derived mononuclear cells were 
obtained from the patient and intracoronary infusion was 
made, in addition to the state-of-the-art interventional ther-
apy. A brief description of several of these trials is shown in 
Table 2. As a whole, a recent systematic review (Abdel-Latif 
et al 2007) and a meta-analysis (Hristov et al  2006) conclude 
that these interventions are feasible, safe, and associated to a 
small increase in left ventricular ejection fraction (LVEF). In 
addition, a recent meta-regression using data from ten studies 
show a dose-response effect for the infused volume when the 
ejection fraction is measured (Lipinski et al 2007).
Limitations of the current state of the evidence highlight 
the lack of consensus about the best technical protocol. The 
vast majority of trials use bone marrow-derive mononuclear 
cells. However, the best volume to extract is unknown. 
Several studies have used peripheral blood-derived mono-
nuclear cells, although bone marrow material is the leading 
source in most trials. Nevertheless, bone marrow mononu-
clear cells include a wide variety of cells beyond EPCs; some 
of them may differentiate towards a pathogenic direction. 
As stated by the European Task Force, technical protocols 
to elucidate the best interventional procedure for progenitor-
induced repair are expected to be time and effort-consuming 
(Bartunek et al 2006). A clinical question to be answered is 
whether intracoronary infusion of EPCs is able to improve 
clinical outcomes beyond surrogate markers (such as left 
ventricular ejection fraction [LVEF]) for a sustained period 
of time. As far as mechanistic studies are concerned, the issue 
to be addressed refers to the exact underlying explanation 
of EPC-mediated beneﬁ  t. A low amount of intramyocardial 
bone marrow mononuclear cells is able to adhere in human 
series using radiolabelling methods, ranging from 9.2% for 
bone marrow-derived CD133+ and 6.8% for bone marrow-
derived CD133+/CD34+ (Goussetis et al 2006) to 5.5% for 
peripheral blood-derived CD34+ at 1 hour after implantation 
(Blocklet et al 2006). This percentage rises to 6.9%–8% 
(2 h) and 2.3%–3.2% (12 h) after intracoronary infusion of 
CD133+ cells after G-CSF mobilization and separation from 
the peripheral blood (Schots et al 2007).
Vascular progenitor modulation 
by current cardiovascular drugs
Statins have been shown to increase the number of CD34+/
KDR+ cells in atherosclerotic patients (Vasa et al 2001a). 
This effect seems to involve the stimulation of PI3K-Akt in 
the bone marrow, which improves microvessel function and 
subsequent EPC release (Dimmeler et al 2001). Interestingly, 
this molecular pathway is uncoupled in the diabetic state 
(Okon et al 2005) and may be responsible for the decreased 
concentration of EPCs in diabetic patients (Fadini et al 
2006). More recent clinical evidence showed that long-term 
and long-dose statin treatment was able to decrease of EPCs 
(measured as CD34+/KDR+) (Hristov et al 2007b). Never-
theless, statin-mediated biphasic effect seems to be associated 
to a late increase of CD34+/CD144+ EPCs, which show a 
potential effect of statins on EPC differentiation from early 
to advanced progenitors (Deschaseaux et al 2007).
Renin-angiotensin system inhibitors have been related to 
EPC mobilization. In vivo infusion of angiotensin II in rats 
was able to induce decrease of EPC count and telomerase 
activity, with a subsequent increase of EPC senescence. 
These effects were inhibited by administration of the 
Table 2 Some clinical trials about the potential therapeutical role 
of EPCs
Study Reference Finding
TOPCARE-AMI Schächinger et al 
2004
8% increase of LVEF 
after 4 months
REPAIR-AMI Schächinger et al 
2006
2.5% increase of LVEF 
after 4 months
BOOST Meyer et al 2006 Similar LVEF after 18 months
ASTAMI Lunde et al 2006 Similar LVEF after 6 months 
(p = 0.054)
TOPCARE-CHD Assmus et al 2007 Decreased mortality after 
577 days
Abbreviations: EPCs, endothelial protector cells; LVEF, left ventricular ejection 
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AT1-blocker valsartan (Imanishi et al 2005). Irbesartan was 
also associated to increased EPC counts (Bahlmann 2005). 
Enalapril was found to increase the bone marrow release of 
early EPC progenitors in a rat model by involving CD26+ 
(dipeptidylpeptidase) enzyme stimulation, which induces 
EPC release (Wang et al 2006a).
Thiazolidinediones (rosiglitazone and pioglitazone) 
are peroxisome proliferator-activated receptor-γ (PPAR-γ) 
agonists which may possess direct and independent car-
diovascular beneﬁ  ts (Erdmann et al 2007), although there 
is a recent concern for potential danger of rosiglitazone-
mediated heart failure in high-risk patients (Lipscombe 
et al 2007). Incubation with rosiglitazone induces in vitro 
endothelial differentiation from a cluster of vascular pro-
genitors (Wang et al 2004). Pioglitazone has been found to 
restore the quantitative and qualitative defect (measured as 
impaired in vitro formation of capillaries) which is found 
in type 2 diabetes patients (Wang et al 2006b). This effect 
may be mediated by a PPAR-γ-dependent increase of EPC 
adhesion under ﬂ  ow (Redondo et al 2007b). This may 
explain the increased EPC counts in diabetic (Wang et al 
2006b) and nondiabetic patients (Werner et al 2007) under 
pioglitazone treatment.
Some antiatherosclerotic drugs have been shown to 
decrease the proliferation of EPC after in vitro incubation. 
Aspirin has been shown to possess this capability at mili-
molar concentrations (Chen et al 2006). This capability is 
also shared by COX-2 inhibitors (Colleselli et al 2006). Rapa-
mycin is a potent in vitro inhibitor of EPC growth (Imanishi 
et al 2006), which may mediate the endothelial damage of 
rapamycin-coated stents (Zhao et al 2008). Future research 
will clear the role of differential progeny, isolation, adhesion 
and differentiation in these cell culture experiments.
Eventually, the physical activity has been proven to 
affect EPC number and function. Physical training in mice 
increased the number of circulating EPCs (Laufs et al 2004) 
being these results reproduced in patients (Steiner et al 2005). 
This is related to increased blood levels of VEGF and SDF 
induced by exercise (Sarto et al 2007). Some results were able 
to correlate exercise-mediated EPC increase with increased 
levels of EPO in trained subjects (Steiner et al 2005). Cardiac 
rehabilitation was equally able to increase EPC CFUs and 
decrease EPC apoptosis (Paul et al 2007).
Vascular progenitor modulation 
by target-designed novel molecules
Being EPC derived from the hematological stem cells 
committed towards the myeloid lineage, one of the 
most intuitive interventions to induce EPC release is 
granulocyte-colony stimulating factor (G-CSF), a stimu-
lus for myeloid recovery (Ossenkoppele et al 2004). Studies 
on animal models were able to show a G-CSF-mediated 
increase of circulating CD34+ cells, which was associated 
to improved angiogenesis and conserved myocardial func-
tion (Ott et al 2005). Treatment with G-CSF treatment was 
able to increase the blood levels of CD34+ cells in coronary 
disease patients (Suarez de Lezo et al 2005) with a related 
improvement in LVEF (Nienaber et al 2006), G-CSF treat-
ment is able to increase CFU capability, although in vitro 
migration remained diminished (Honold et al 2006). The 
randomized REVIVAL-2 trial was unable to ﬁ  nd a signiﬁ  -
cant change on infarct size, LVEF, or coronary obstruction 
(Zohlnhöfer et al 2006). The STEMMI trial was equally 
unable to ﬁ  nd a signiﬁ  cant beneﬁ  t for G-CSF treatment 
(Ripa et al 2006). Advanced age may dampen the efﬁ  cacy 
of G-CSF to increase EPC number and/or function (Lehrke 
et al 2006).
Another approach is the usage of G-CSF to enrich EPC 
extraction by apheresis, as a puriﬁ  ed source of EPCs for thera-
peutical intracoronary infusion (Ripa et al 2007). However, 
in addition to the well-known side effects of G-CSF (such as 
bone pain and inﬂ  uenza-like syndrome), the inﬂ  ammatory 
state of atherosclerotic lesions might be increased due to 
the unspeciﬁ  c release of leukocytes from the bone marrow, 
with an initial strengthened release of monocytes (Parissis 
et al 2006).
Another approach to increase EPC release from the bone 
marrow is AMD3100, a small molecule which antagonizes 
the binding of SDF and CXCR4. Animal experimental evi-
dence shows a signiﬁ  cant increase of CD34+ (Burroughs et al 
2005), being these results reproduced in human volunteers 
(Liles et al 2005; Flomenberg et al 2005). Nevertheless, 
caution should be addressed for the implementation of his 
compound, since it may also inhibit EPC homing from the 
blood to the denuded vessel (Yin et al 2007) and increase 
unspeciﬁ  c leukocyte release, which may increase plaque fra-
gility (Zernecke et al 2008).
Another substance to increase EPC number and function 
is erythropoietin (EPO). In animal experimental ischemia, 
EPO has been found to possess infarct-limiting effect 
(Moon et al 2003) and thus maintain LVEF (Scheneider 
et al 2007). In addition to the direct protective effect for 
myocytes (Hanlon et al 2005), EPO is able to increase EPC 
blood concentration in mice models of ischemia (Urao et al 
2006). A single bolus of EPO has been shown to increase 
blood number of EPCs (CD34+/CD45−) in patients with acute Biologics: Targets & Therapy 2008:2(3) 403
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myocardial infarction, although LVEF remains the same after 
four months (Lipsic et al 2006).
Current efforts are being made in order to obtain 
compounds which affect EPC release, adhesion and 
differentiation in a selective manner. According to this 
approach, a cGRD (cyclic Arg-Gly-Asp) peptide-coated 
stent was found to selectively induce EPC adhesion in por-
cine coronary arteries and inhibit neointimal hyperplasia 
(Blindt  et al 2006).
Vascular implications in hematological 
malignancies
Experimental (Fischer et al 2007) and clinical (Cohen 
et al 2007) evidence showed the therapeutical value 
of antiangiogenic cancer treatment. In hematological 
malignancies, multiple myeloma is the paradigm of neo-
plasic disease where antiangiogenic therapy has been 
established in the state-of-the-art clinical practice, with tha-
lidomide (Facon et al 2007) and lenalidomide (Dimopoulos 
et al 2007). Increased EPC numbers are correlated to the 
clinical outcome in multiple myeloma, being decreased 
after thalidomide treatment (Zhang et al 2005). Moreover, 
a signiﬁ  cant population of myeloma patients possesses 
circulating EPCs which come from the neoplasic clone 
(Rigolin et al 2006).
These results about the clonal (neoplasic) origin of a sub-
stantial population of tumor growth-related endothelial cells 
has equally been found in chronic myelogenous leukemia, 
where bcr-abl protein was found in endothelial cells generated 
in vitro from the bone marrow of six patients (Gunsilius et al 
2000). Further evidence was able to identify a bone marrow 
chronic myelogenous leukemia progenitor with hemangio-
blast capability (Fang et al 2005). Imatinib (bcr-abl blocker) 
may possess some degree of angiogenic-related mechanism 
of action, since it has been shown to decrease cell secretion 
of VEGF in cell culture studies (Ebos et al 2002).
Conclusion and clinical 
perspective
Despite the increase in our knowledge of atherosclerosis, 
cardiovascular mortality remains as the ﬁ  rst cause of death. 
Research on the role of blood and marrow in atherosclerosis 
may lead to the implementation of novel, independent and 
speciﬁ  c risk factors for the early diagnose and treatment 
monitoring. Moreover, current discoveries on the regulation 
of vascularization and ischemia are expected to generate 
a rational therapeutical approach to control hematological 
malignancies.
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